Ayala Pharmaceuticals Inc (ADXS)

[mypekeispooped]

Um...Amgen paid $40Mil up front. The AXAL GOG Study 0265 had 12 month overall survival of 38% which beat the historical 30%. The Phase 1/2 Brown study in high risk advanced anal cancer had all patients who completed RT and received treatment achieve a CR at
six months. The historical 3 year recurrence rate is around 45%. By the chart included in the corporate presentation 5 of the 9 appear to have already exceeded that timeframe. If AXAL didn't work, how do you explain the results? You may wish to do at least some cursory DD before making such allegations.